258 Chapter 11 Studies with synchronous and metachronous peritoneal metastases population Reference Level of Testing Genes or Panel Investigated Type of Analysis Gene or Molecule Name and Mutation or Expression Status (n) No. of Patients with PM (N) with Outcomes (n) No. of Patients without PM (N) with Corresponding Outcomes (n) MMR Status (MSI/ MSS) Findings as Reported by Authors in Studies Synch. Metach. Christensen et al. 44 DNA RAS (KRAS and NRAS), BRAF and PIK3CA NGS or Mutation kit and PS N = 43 N = 33 N = 372 N/A PIK3CA mutations were significantly associated with absence of PM (OR = 0.10; 95%CI = 0.01–0.79, p = 0.028 g) and with a decreased hazard of developing PM (HR = 0.31; 95%CI = 0.110.86, p = 0.024 g). The hazard ratio of developing PM and having BRAF mutations were not associated with PM (OR = 2.07; 95%CI = 0.60-6.19, p = 0.192 g and (HR = 1.82; 95%CI = 0.81–4.08, p = 0.146 g).). RAS mutant (206) 21 16 169 BRAF V600E mutant (30) 7 3 20 PIK3CA mutant (61) 1 3 57 Table 3. Continued
RkJQdWJsaXNoZXIy MTk4NDMw